Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC.MIRA · Entity 7362 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MIRA PHARMACEUTICALS, INC.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2036-06-12 | Direct | 50,000 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 50,000 · Balance 50,000 F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026. F2: The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date. F3: Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.
F2: The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.
F3: Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 21:00 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001493152-26-028714 · ownership.xml · derivative · entry 1 Shekhat Denil Nanji · CIK 0002016605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-06-12 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date. F3 · balance_after: Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each. Read SEC document |
| October 01, 2025 Filed Oct 4, 2025 00:00 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantCommon Stock | 22,378 | $1.35 | $30,210.30 |
DisclosureSEC source: 0001493152-25-016958 · ownership.xml · nonDerivative · entry 1 Shekhat Denil Nanji · CIK 0002016605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,378 F1 · security: Represents 22,378 restricted shares of common stock, par value $0.0001 of the Issuer issued as compensation for the Issuer's acquisition of SKNY Pharmaceuticals, Inc. F1 · price: Represents 22,378 restricted shares of common stock, par value $0.0001 of the Issuer issued as compensation for the Issuer's acquisition of SKNY Pharmaceuticals, Inc. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 22:15 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001493152-24-049506 · ownership.xml · derivative · entry 1 Shekhat Denil Nanji · CIK 0002016605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-12-09 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date. F3 · balance_after: Represents 50,000 stock options that were issued to the Reporting Person on December 6, 2024, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $1.19 each. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 20:30 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantNonqualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001493152-24-024753 · ownership.xml · derivative · entry 1 Shekhat Denil Nanji · CIK 0002016605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,666 Underlying: Common Stock · 50,000 shares Expires 2034-06-18 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the Nasdaq Official Closing Price of the Issuer's common stock on June 18, 2024, the date of the grant. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on June 18, 2024, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"), and in accordance with the terms of a consulting agreement dated June 18, 2024, by and between the Reporting Person and MIRA Pharmaceuticals, Inc. The stock options will vest in three equal tranches, with the first tranche vesting immediately on the grant date of June 18, 2024, the second tranche vesting on December 18, 2024, and the final tranche vesting on June 18, 2025. F3 · balance_after: Represents (i) 25,000 stock options that were issued to the Reporting person on March 25, 2024, that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $1.16 each and (ii) 16,666 stock options that were issued to the Reporting Person on June 18, 2024, that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.71 each. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 21:53 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantNonqualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001493152-24-011572 · ownership.xml · derivative · entry 1 Shekhat Denil Nanji · CIK 0002016605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 50,000 shares Expires 2034-03-25 F1 · derivative.exercise_date: The options were granted under the Issuer's 2022 Omnibus Incentive Plan whereby 50% of such options, or 25,000 options, vested immediately on the grant date of March 25, 2024, and the remaining 50% vest on the first anniversary of the grant date, March 25, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.